Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies

Do statins harm the brain? A persistent fear — amplified by lawsuits and anecdote — says they might. This meta-analysis of 36 observational studies finds the opposite signal.

Pooling the data, statin users had a 20% lower risk of all-cause dementia and a 32% lower risk of Alzheimer’s disease than non-users. Far from the cognitive harm some feared, the association points toward possible protection.

The practical takeaway is reassurance: the evidence does not support stopping or avoiding statins over cognitive worries, and there may even be a benefit worth testing properly. The status-quo friction runs against the anti-statin narrative and the litigation built on it.

We rate the evidence moderate: a large, statistically robust meta-analysis, but built entirely on observational studies, which can’t fully exclude confounding (healthier people may both take statins and stay sharp). The authors’ lipid-research affiliations are worth noting. Its clinical significance is solid as reassurance for the millions on statins — though the tantalizing protective signal needs randomized trials before it’s more than a hypothesis.